Experts disagree on whether prostate cancer with a Gleason score of 6 (GS6) should be re-labeled as non-cancerous. Writing in a commentary in the Journal of Clinical Oncology, Scott Eggener, MD, and ...

Bottom Line: Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...